Training and Resources
KEYTRUDA® (pembrolizumab) in metastatic non-small cell lung cancer (NSCLC)
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
KEYTRUDA® plus chemotherapy
Discover what 5-year follow up data might mean for your eligible Squamous and non-Squamous mNSCLC patients?
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
KEYNOTE-189: what the 4-year follow-up data might mean for your eligible non-squamous mNSCLC patients
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
Take a closer look at your untreated PD-L1 non-expressing mNSCLC patients: meet Bill
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
Take a closer look at your untreated squamous PD-L1 negative mNSCLC patients: meet Bob
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
A guide to managing your metastatic non-small cell lung cancer patients on KEYTRUDA® (pembrolizumab) plus chemotherapy
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
KEYTRUDA® monotherapy
Patient management
KEYLearning Hub: digestible peer-to-peer videos on managing mNSCLC patients on KEYTRUDA® plus chemotherapy
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
A guide to managing your metastatic non-small cell lung cancer patients on KEYTRUDA® (pembrolizumab) plus chemotherapy
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
More information about KEYTRUDA® (pembrolizumab) in advanced NSCLC
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
